Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 18/20 | 0.81 |
| ▸ | PPARG | P37231 | 16/20 | 0.81 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Muraglitazar SCHEMBL676469 | 0.90 | PPARA (1.00) | PPARAPPARG | |
| SCHEMBL14599062 | 0.89 | PPARG (0.85) | PPARAPPARG | |
| SCHEMBL13722049 | 0.88 | PPARA (0.93) | PPARAPPARG | |
| SCHEMBL6342308 | 0.86 | PPARA (0.87) | PPARAPPARG | |
| SCHEMBL13718146 | 0.86 | PPARA (0.93) | PPARAPPARG | |
| SCHEMBL6073227 | 0.84 | PPARA (0.90) | PPARAPPARG | |
| SCHEMBL13720646 | 0.84 | PPARA (0.67) | PPARAPPARG | |
| SCHEMBL13720928 | 0.84 | PPARA (0.74) | PPARAPPARG | |
| SCHEMBL6073514 | 0.84 | PPARA (0.88) | PPARAPPARG | |
| SCHEMBL8215885 | 0.84 | PPARA (0.88) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060177444-A1 | Concomitant drug as therapeutic agent for inflammatory bowel disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1607103-A1 | CONCOMITANT DRUG AS THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE | Eisai Co., Ltd. (JP) | 2005-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060177444-A1 | Concomitant drug as therapeutic agent for inflammatory bowel disease | PPARG, PPARA, NR3C1 | PPARA 2/4885PPARG 1/4885FFAR1 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.